[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100497416":3},{"organization":4,"armGroups":7,"interventions":29,"overallOfficials":48,"centralContacts":53,"locations":63,"responsibleParty":89,"collaborators":91,"id":94,"slug":95,"hasResults":96,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":58,"eligibilityCriteria":100,"healthyVolunteers":96,"sex":101,"minAge":102,"maxAge":103,"enrollmentInfo":104,"targetDuration":58,"studyType":107,"phases":108,"briefSummary":110,"conditions":111,"keywords":58,"overallStatus":66,"whyStopped":58,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Beijing Airdoc Technology Co., Ltd.","INDUSTRY",[8,15,20,24],{"label":9,"type":10,"description":11,"interventionNames":12},"PBM therapy + SVS","EXPERIMENTAL","Low lever red light therapy with single vision spectacles",[13,14],"Device: PBM","Device: Single vision spectacles",{"label":16,"type":10,"description":17,"interventionNames":18},"Peripheral defocus spectacles","a spectacles with special design with peripheral myopic defocus to control myopia progression",[19],"Device: Peripheral defocus spectacles",{"label":21,"type":10,"description":22,"interventionNames":23},"PBM +Peripheral defocus spectacles","Low lever red light therapy with a spectacles with special design with peripheral myopic defocus to control myopia progression",[13,19],{"label":25,"type":26,"description":27,"interventionNames":28},"Control","PLACEBO_COMPARATOR","single vision spectacles only as the control",[14],[30,37,42],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":35},"DEVICE","PBM","PBM, is a low intensity red light at wavelength of 650nm; Peripheral defocus spectacels is a peripheral design glasseses for correct myopia and control myopia",[21,9],[36],"Low lever light therapy; low intensity red light therapy; low lever laser therapy; repeated red light therapy",{"type":31,"name":16,"description":38,"armGroupLabels":39,"otherNames":40},"plus power design of many peripheral small lenses to achieve myopic defocus of the retina in the peripheral retina",[21,16],[41],"Myopic defocus spectacles for myopia control",{"type":31,"name":43,"description":44,"armGroupLabels":45,"otherNames":46},"Single vision spectacles","Distance vision correction with the single vision spectacles for the myopia correction methods (glasseses for myopia correction)",[25,9],[47],"single vision glasseses for myopia correction lenses",[49],{"name":50,"affiliation":51,"role":52},"Yan Wang, BA","The First People's Hospital of Xuzhou","STUDY_DIRECTOR",[54,60],{"name":55,"role":56,"phone":57,"phoneExt":58,"email":59},"Ying Li, MD, PHD","CONTACT","+8615162130727",null,"834582241@qq.com",{"name":61,"role":56,"phone":62,"phoneExt":58,"email":58},"Lei Qiao, PHD, MD","+15162127602",[64],{"facility":65,"status":66,"city":67,"state":68,"zip":69,"country":70,"countryCode":71,"cosmosGeoPoint":72,"geoPoint":77,"contacts":78},"the first people's hospital of Xuzhou","RECRUITING","Xuzhou","Jiangsu","210000","China","CN",{"type":73,"coordinates":74},"Point",[75,76],117.28386,34.20442,{"lat":76,"lon":75},[79,81,84,87],{"name":80,"role":56,"phone":57,"phoneExt":58,"email":59},"Ying Li, MD.Ph.D.",{"name":82,"role":83,"phone":58,"phoneExt":58,"email":58},"Weiming Yang, MD. PhD","SUB_INVESTIGATOR",{"name":85,"role":86,"phone":58,"phoneExt":58,"email":58},"Xiaoying Wang, MD. PhD.","PRINCIPAL_INVESTIGATOR",{"name":88,"role":86,"phone":58,"phoneExt":58,"email":58},"Xingtao Zhou, MD. PhD",{"type":90,"investigatorFullName":58,"investigatorTitle":58,"investigatorAffiliation":58,"oldNameTitle":58,"oldOrganization":58},"SPONSOR",[92],{"name":51,"class":93},"OTHER","100497416","myopia-control-combined-pbm-with-myopic-defocus-lens-in-children-100497416",false,"NCT05756959","Myopia Control Combined PBM With Myopic Defocus Lens in Children","Myopia Control Combined PBM With Myopic Defocus Lens in Children: Double-blind RCT for 6 Month","Inclusion Criteria:\n\n* Informed consent by the supervision of the children\n* 6\\~13 years old (including both the 6 and 13)\n* SE range: -0.50\\~-5.50D\n* Astigmatism \\\u003C=2.00D\n* BCVA \\>=0.8\n* Anisometropia \\\u003C=1.50D\n* Confirmed to no use of other myopia control intervention\n\nExclusion Criteria:\n\n* Ocular lesions to effect vision or diseases (such as cataract, glaucoma, marcular pathology, cornea lesions, uveitis, retina detachment, congential opitc abnormal and etc.)\n* Halo, glare, toutic, ADHD, psoriasis\n* Systom disease: immune disease, central nerve system, Down syndrome, asthma, severe cardiopulmonary abnormal, severe liver and renal dysfunction.\n* Squint, ocular lesion or acute imflammation.\n* Other myopia control interventions within recent 3 month such as atropine, device, orthokeratology, multi-focus soft lens, multi-function spectacles.","ALL","6 Years","13 Years",{"count":105,"type":106},304,"ESTIMATED","INTERVENTIONAL",[109],"NA","To study the efficacy of myopi control with two methods: low lever red light and peripheral defocus spectacles with four groups and design with prospective, double-blind, randimized, and with control for 6 month.",[112],"Myopia, Progressive","2023-03-07",{"date":115,"type":116},"2023-03-09","ACTUAL",{"date":118,"type":116},"2022-12-12",{"date":120,"type":106},"2027-12-31",{"name":5,"class":6},1]